EGFR and non-small cell lung carcinoma: Although the limited sample size of subgroup analysis for both trials necessitates cautious interpretation of the findings and restricts their generalization, the promising efficacy of combination therapy in EGFR-mutant NSCLC with concomitant TP53 mutation warrants further verification in prospective randomized clinical trials.